Tradestie Institutional Equity Comparison Engine

KTTA vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Momentum & Technical while KTTA counters with relative strength in Options & Structure. Fundamentally, KTTA trades at N/M Forward P/E with 0.0% operating margin (+1498.1% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
KTTA N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY +1498.1% vs +0.0%
Momentum & Technical Winner ANRO
1Y +0.6% vs +63.3% ยท 52W Pos 11% vs 52%
Options & Structure Winner KTTA
UNCLASSIFIED (N/A IV) vs BREAKDOWN (8th %ile IV)
KTTA NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
1M Return +7.52%
1Y Return +0.59%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
1M Return +14.28%
1Y Return +63.26%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KTTA +0.59% ANRO +63.26% Spread: +62.67 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
KTTA TTM Op. Margin: 0.0% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KTTA vs ANRO. Trailing 12-month operating profitability (KTTA 0.0% vs ANRO 0.0%) and valuation multiples (KTTA N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KTTA (1) vs ANRO (5)
Institutional Metric KTTA ANRO Criterion Row Winner
Market Capitalization Scale $17.7M $1.1B Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +1498.1% +0.0% Higher Growth KTTA
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -88.8% -46.7% Higher ROE ANRO
52-Week Range Position Momentum 11% ($0โ€“$2) 52% ($13โ€“$37) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 185% Vol 1.86ฮฒ ยท 91% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite ANRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KTTA vs ANRO Buy Guide
KTTA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KTTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
61d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KTTA nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.